Compare ARI & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARI | NRIX |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2009 | 2020 |
| Metric | ARI | NRIX |
|---|---|---|
| Price | $10.13 | $18.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $10.83 | ★ $26.50 |
| AVG Volume (30 Days) | 828.7K | ★ 1.6M |
| Earning Date | 10-30-2025 | 01-27-2026 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $269,296,000.00 | $83,687,000.00 |
| Revenue This Year | $25.91 | $58.38 |
| Revenue Next Year | $14.63 | N/A |
| P/E Ratio | $11.44 | ★ N/A |
| Revenue Growth | ★ 67.16 | 48.32 |
| 52 Week Low | $7.70 | $8.18 |
| 52 Week High | $11.11 | $22.95 |
| Indicator | ARI | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 54.46 | 74.70 |
| Support Level | $10.02 | $16.02 |
| Resistance Level | $10.18 | $17.79 |
| Average True Range (ATR) | 0.15 | 1.09 |
| MACD | 0.03 | 0.16 |
| Stochastic Oscillator | 64.42 | 96.31 |
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that primarily originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.